Entries by Carme Lopez

Salvat Laboratories presented Phase III clinical trials results of Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery at the 2023 ARVO Annual Meeting

24/05/2023 in , , /by

Salvat Laboratories, the international pharmaceutical company focused on the development, manufacturing, and commercialization of ophthalmology treatments, announced the results of phase III clinical trials of its most potent ophthalmic corticosteroid in the global ophthalmology market at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting held from 23-27 April 2023 in New Orleans. […]

Salvat Laboratory submits application to the U.S. FDA for approval of Clotrimazole, a pioneering drug for the treatment of otomycosis

01/12/2022 in , , /by

The new drug will be the only one on the market in the United States and Europe specifically formulated and indicated for the topical treatment of fungal otitis externa. Salvat has invested 22 million euros in this project with which reinforces its position as a leading laboratory in the field of otology at an international […]

Salvat Laboratories announces submission of New Drug Application to the U.S. FDA for Clobetasol Nanoemulsion for treating inflammation and pain after ocular surgery

25/10/2022 in , , /by

Salvat Laboratories, the international company which developed and owns the globally commercialized products Otovel and Cetraxal, today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients. […]

Salvat, pioneer in using cell-therapy for the treatment of non-consolidated bone fractures (BONECURE project)

07/09/2022 in , , /by

It is an innovative project based on pre-differentiated mesenchymal stem cells designed to treat patients with bone consolidation problems post-fracture (atrophic pseudoarthrosis). A Phase II clinical trial has been completed, with very promising results in terms of efficacy and safety, in patients with pseudoarthrosis of long bones. Salvat has invested more than 10 million Euros […]

Salvat plans to launch the first global ocular corticosteroid with nanoemulsion in 2023 for the inflammation and pain after ocular surgery

21/04/2022 in , , /by

Phase III clinical trials conducted in US confirm that clobetasol is effective and safe in the treatment of inflammation and pain after cataract surgery. The pharmaceutical company has begun the process with health authorities to market the new corticosteroid worldwide by the middle of next year. The company has patented a pioneering technology, IMPACT-SVT®, which […]

The Secretary General for Industry visits the Pharmaloop plant

23/04/2021 in , , /by

Mr. Raúl Blanco, Secretary General for Industry and Small and Medium Enterprises, visited Pharmaloop’s new sterile liquids plant, located in Alcalá de Henares (Madrid). Pharmaloop is the first fully autonomous pharmaceutical production center in Spain, with a natural gas cogeneration system that creates its own energy. The visit served to reinforce the company’s commitment to […]

Salvat’s Pharmaloop Invests 65 million Euros in Its New Sterile Liquids Plant, located in Alcalá de Henares

18/02/2021 in , , /by

The Minister of Industry, Reyes Maroto, visited Salvat’s new facility today, accompanied by the Mayor of Alcalá de Henares, Javier Rodriguez Palacios and Salvat CEO, Alberto Bueno The new 8,500 m² plant is equipped with the most advanced technology, highest quality standards and the capacity to produce more than 350 million units of sterile formulations […]